scholarly journals Adaptation of a chemosensitivity assay to accurately assess pemetrexed in ex vivo cultures of lung cancer

2013 ◽  
Vol 14 (1) ◽  
pp. 39-44 ◽  
Author(s):  
Sarah L. Suchy ◽  
Rodney J. Landreneau ◽  
Matthew J. Schuchert ◽  
Dakun Wang ◽  
Paul R. Ervin Jr. ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Ex Vivo ◽  
Chemosensitivity Assay

scholarly journals Ex vivo model of non‑small cell lung cancer using mouse lung epithelial cells

2017 ◽  
Author(s):  
Taku Sato ◽  
Mami Morita ◽  
Ryota Tanaka ◽  
Yui Inoue ◽  
Miyuki Nomura ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epithelial Cells ◽  
Small Cell Lung Cancer ◽  
Ex Vivo ◽  
Small Cell ◽  
Lung Epithelial Cells ◽  
Mouse Lung ◽  
Small Cell Lung ◽  
Ex Vivo Model ◽  
Lung Epithelial

scholarly journals Baicalin suppresses lung cancer growth by targeting PDZ-binding kinase/T-LAK cell-originated protein kinase

2019 ◽  
Vol 39 (4) ◽  
Author(s):  
Xin Diao ◽  
Danfen Yang ◽  
Yu Chen ◽  
Wentian Liu
Keyword(s):  
Lung Cancer ◽  
Protein Kinase ◽  
Cancer Cells ◽  
Ex Vivo ◽  
Lung Cancer Cells ◽  
Cancer Growth ◽  
Downstream Signaling ◽  
Lak Cell

AbstractBaicalin is the main bioactive component extracted from the traditional Chinese medicine Baical Skullcap Root, and its anti-tumor activity has been studied in previous studies. PDZ-binding kinase/T-LAK cell-originated protein kinase (PBK/TOPK), a serine/threonine protein kinase, is highly expressed in many cancer cells and stimulates the tumorigenic properties, and so, it is a pivotal target for agent to cure cancers. We reported for the first time that baicalin suppressed PBK/TOPK activities by directly binding with PBK/TOPK in vitro and in vivo. Ex vivo studies showed that baicalin suppressed PBK/TOPK activity in JB6 Cl41 cells and H441 lung cancer cells. Moreover, knockdown of PBK/TOPK in H441 cells decreased their sensitivity to baicalin. In vivo study indicated that injection of baicalin in H441 tumor-bearing mice effectively suppressed cancer growth. The PBK/TOPK downstream signaling molecules Histone H3 and ERK2 in tumor tissues were also decreased after baicalin treatment. Taken together, baicalin can inhibit proliferation of lung cancer cells as a PBK/TOPK inhibitor both in vitro and in vivo.

scholarly journals Ex Vivo Four-Dimensional Lung Cancer Model Mimics Metastasis

2015 ◽  
Vol 99 (4) ◽  
pp. 1149-1156 ◽  
Author(s):  
Dhruva K. Mishra ◽  
Chad J. Creighton ◽  
Yiqun Zhang ◽  
Fengju Chen ◽  
Michael J. Thrall ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Ex Vivo ◽  
Cancer Model ◽  
Lung Cancer Model

683: Ex vivo modelling of Kras-driven murine non-small cell lung cancer

2014 ◽  
Vol 50 ◽  
pp. S164
Author(s):  
K. Närhi ◽  
E. Parri ◽  
A. Nagaraj ◽  
P. Kovanen ◽  
R. Turkki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Ex Vivo ◽  
Small Cell ◽  
Small Cell Lung

Circulating Tumor Cells in Small Cell Lung Cancer: Ex Vivo Expansion

Lung ◽  
2015 ◽  
Vol 193 (3) ◽  
pp. 451-452 ◽  
Author(s):  
Gerhard Hamilton ◽  
Otto Burghuber ◽  
Robert Zeillinger
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cell Lung Cancer ◽  
Ex Vivo ◽  
Ex Vivo Expansion ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer

2019 ◽  
Vol 216 (9) ◽  
pp. 2128-2149 ◽  
Author(s):  
James Clarke ◽  
Bharat Panwar ◽  
Ariel Madrigal ◽  
Divya Singh ◽  
Ravindra Gujar ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Single Cell ◽  
Ex Vivo ◽  
Cell Subset ◽  
Chromatin Accessibility ◽  
Transcriptomic Analysis ◽  
Human Lung Cancer ◽  
Normal Lung ◽  
Molecular Characteristics ◽  
Resident Memory T Cells

High numbers of tissue-resident memory T (TRM) cells are associated with better clinical outcomes in cancer patients. However, the molecular characteristics that drive their efficient immune response to tumors are poorly understood. Here, single-cell and bulk transcriptomic analysis of TRM and non-TRM cells present in tumor and normal lung tissue from patients with lung cancer revealed that PD-1–expressing TRM cells in tumors were clonally expanded and enriched for transcripts linked to cell proliferation and cytotoxicity when compared with PD-1–expressing non-TRM cells. This feature was more prominent in the TRM cell subset coexpressing PD-1 and TIM-3, and it was validated by functional assays ex vivo and also reflected in their chromatin accessibility profile. This PD-1+TIM-3+ TRM cell subset was enriched in responders to PD-1 inhibitors and in tumors with a greater magnitude of CTL responses. These data highlight that not all CTLs expressing PD-1 are dysfunctional; on the contrary, TRM cells with PD-1 expression were enriched for features suggestive of superior functionality.

Interleukin-2 with Ex Vivo Activated Killer Cells: Therapy of Advanced Non-Small-Cell Lung Cancer

1991 ◽  
Vol 10 (5) ◽  
pp. 383-387 ◽  
Author(s):  
Z P Bernstein ◽  
M H Goldrosen ◽  
L Vaickus ◽  
N Friedman ◽  
H Watanabe ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Ex Vivo ◽  
Interleukin 2 ◽  
Small Cell ◽  
Small Cell Lung ◽  
Killer Cells

Activation of CD8+ tumor infiltrating lymphocytes by bavituximab in a 3D ex vivo system of lung cancer patients.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 3060-3060 ◽  
Author(s):  
Soner Altiok ◽  
Melanie Mediavilla Valera ◽  
Jenny Kreahling ◽  
David Noyes ◽  
Tiffany N Razabdouski ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Ex Vivo ◽  
Tumor Infiltrating Lymphocytes ◽  
Lung Cancer Patients ◽  
Infiltrating Lymphocytes
Sign in / Sign up

Export Citation Format

Share Document